article thumbnail

How the New EU AI Act Will Impact Clinical Trials in the Life Sciences?

Cloudbyz

This Act is poised to significantly change the clinical trials landscape within the life sciences sector. As AI increasingly becomes a cornerstone in clinical research and drug development, it is crucial for industry stakeholders to grasp the extensive implications of this regulation.

article thumbnail

Hidden compliance risks for life sciences companies

pharmaphorum

The life sciences history industry has some unique challenges when it comes to compliance. But if you think third party compliance risks are bad, don’t take your eye off fourth and fifth parties, says Allan Matheson. In 2020, life science firms accounted for a third of the SEC’s enforcement actions.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Patient-Centric Marketing in the Life Science Industry: Putting the Focus on Patient Needs

Pharma Mirror

Compliance with complex laws and regulations, like Direct-to-Consumer Advertising (DTCA) Rules or the Health Insurance Portability and Accountability Act (HIPAA), can be quite daunting. And it is not hard to see why.

article thumbnail

The criticality of compliance

pharmaphorum

Remaining compliant is imperative to the life sciences industry, so adhering to regulatory requirements is mandatory. Prior to selling drugs or medical products in any country, pharmaceutical companies must prove compliance and gain the regulatory approval required by the country in which the goods will be distributed in.

article thumbnail

Thirty years of the Patented Medicines (Notice of Compliance) Regulations

Pharma in Brief

This year marks the 30-year anniversary of the Patented Medicines (Notice of Compliance) Regulations ( Regulations ), introduced in 1993 to prevent patent infringement by linking the regulatory approval of generic or biosimilar drugs with the patent rights of innovators.

article thumbnail

Interview with Indegene: Challenges and future of pharmacovigilance (PV) Compliance

Outsourcing Pharma

OSP spoke to Vladamir Penkrat, head of safety and regulatory and Shuba Rao a senior director at Indegene, a life sciences digital company about a paper they recently published called 'Challenges and Future of PV Compliance' about the direction compliance is headed and how they would convert risk-based approaches into a confidence-based assurances. (..)

article thumbnail

How AI/ML-based PHI & PII redaction solutions can help life sciences organizations

Cloudbyz

In today’s digital age, life sciences organizations are collecting, storing, and processing vast amounts of sensitive data, including personally identifiable information (PII) and protected health information (PHI). As such, it’s becoming increasingly challenging for organizations to manage and secure this data.